Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy
| العنوان: | Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy |
|---|---|
| المؤلفون: | V Padrun, Richard C. Mulligan, Frank Schwenter, P. Luy, J S Lee, N. Bouche, Nicolas Mach, Philippe Morel, Shohreh Zarei |
| المصدر: | Cancer Gene Therapy, Vol. 18, No 8 (2011) pp. 553-62 |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Cancer Research, Metastatic Melanoma, medicine.medical_treatment, Pulsed Dendritic Cells, Pharmacology, Clinical-Trial, cell encapsulation, Tumor-Cells, Cryopreservation, Mice, In vivo, Cell Line, Tumor, Neoplasms, medicine, cytokine, Erythropoietin Delivery, Animals, Humans, immunostimulation, ddc:612, Cell encapsulation, Molecular Biology, drug release, ddc:616, genetic engineering, Mice, Inbred BALB C, ddc:617, Microencapsulated Islet Grafts, business.industry, Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Phase-I Trial, Immunotherapy, Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage/chemistry/genetics/immunology, Colony-stimulating factor, Cytokine, Neoplasms/genetics/immunology/therapy, Immunology, Immunotherapy/methods, Molecular Medicine, Cytokine secretion, Female, business, K562 Cells, Adjuvant, Human Primary Fibroblasts, Vivo Gene-Transfer |
| الوصف: | Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant in autologous cell-based anti-tumor immunotherapy has recently been approved for clinical application. To avoid the need for individualized processing of autologous cells, we developed a novel strategy based on the encapsulation of GM-CSF-secreting human allogeneic cells. GM-CSF-producing K562 cells showed high, stable and reproducible cytokine secretion when enclosed into macrocapsules. For clinical development, the cryopreservation of these devices is critical. Thawing of capsules frozen at different time points displayed differences in GM-CSF release shortly after thawing. However, similar secretion values to those of non-frozen control capsules were obtained 8 days after thawing at a rate of >1000 ng GM-CSF per capsule every 24 h. For future human application, longer and reinforced capsules were designed. After irradiation and cryopreservation, these capsules produced >300 ng GM-CSF per capsule every 24 h 1 week after thawing. The in vivo implantation of encapsulated K562 cells was evaluated in mice and showed preserved cell survival. Finally, as a proof of principle of biological activity, capsules containing B16-GM-CSF allogeneic cells implanted in mice induced a prompt inflammatory reaction. The ability to reliably achieve high adjuvant release using a standardized procedure may lead to a new clinical application of GM-CSF in cell-based cancer immunization. Cancer Gene Therapy (2011) 18, 553-562; doi:10.1038/cgt.2011.22; published online 13 May 2011 |
| تدمد: | 1476-5500 0929-1903 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::902a232c3d421966b75bd2008fb36044Test https://pubmed.ncbi.nlm.nih.gov/21566667Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....902a232c3d421966b75bd2008fb36044 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765500 09291903 |
|---|